Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 17,007

Document Document Title
WO/2009/114597A1
Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided...  
WO/2009/105691A3
Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid...  
WO/2009/104388A1
Disclosed is a prophylactic/therapeutic agent for collagenosis, which can inhibit the function of TREM-1 to exhibit a prophylactic/therapeutic effect on collagenosis. Also disclosed is a method for the screening of a prophylactic/therape...  
WO/2009/104807A1
In one embodiment, provided is a composition comprising a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is a composition compri...  
WO/2009/105691A2
Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid...  
WO/2009/101399A1
A method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method compri...  
WO/2009/101137A1
We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well a...  
WO/2009/099326A1
The current invention provides for methods and medicaments that apply an oligonucleotide comprising aninosine and/or an uracile and/or a nucleotide containing a base able to form a wobble base pair, said oligonucleotide being preferably ...  
WO/2009/098533A1
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/098577A2
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/098577A3
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/095378A1
The invention provides methods for the diagnosis and treatment of musculoskeletal disorders relating to the Hedgehog pathway, including but not limited to muscular dystrophy (e.g., Duchenne Muscular Dystrophy) using agents that agonize S...  
WO/2009/079741A1
Mammalian cells express heat shock proteins (HSPs) in response to various stresses, such as exercise. Recent studies suggest that expression of heat shock proteins in general, and HSP72 in particular, play a role in muscular hypertrophy....  
WO/2009/079562A2
The present invention relates to compositions and methods for treating and preventing skeletal muscle deficiencies. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188 - P188) and methods...  
WO/2009/079562A3
The present invention relates to compositions and methods for treating and preventing skeletal muscle deficiencies. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188 - P188) and methods...  
WO/2009/073944A1
Disclosed is the use of pyridoxine α-hydroxyisocaproate for attenuating metabolic acidosis and decreasing ammonia accumulation in blood and muscle. As a result of this action, there is a reduction in central and muscular fatigue and a d...  
WO/2009/073947A1
The present invention relates to stable salts of β -alanine and an organic acid selected from the group consisting of malate, citrate and fumarate, endowed with enhanced nutritional and/or therapeutical efficacy in respect to their indi...  
WO/2009/073942A1
A nutritional composition comprising at least an effective amount of trigonelline or derivative of trigonelline and an effective amount of tropane alkaloids, wherein the ingredients act substantially simultaneously improve the consistenc...  
WO/2009/071405A1
The present invention relates to the treatment of patients suffering from cachexia as a comorbidity of cancer using megestrol acetate (MA), in particular using megestrol acetate oral suspension (MegaceTM), more precisely using the advanc...  
WO/2009/068689A2
The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.  
WO/2009/068689A3
The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.  
WO/2009/069736A1
Disclosed is a nitrogenated compound represented by the formula (I) [wherein A represents an aryl which may have a substituent or the like; B's independently represent a hydrogen atom, a halogen or the like; n represents an integer of no...  
WO/2009/065854A1
This invention relates to N-acylhydrazone derivatives (I), which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the tre...  
WO/2009/066457A1
Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof ...  
WO/2009/062683A1
The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17- (OR4)-3-one structure for prophylactic and/or therapeutic uses, wherein R4 is hydrogen or an unsubstituted or subs...  
WO/2009/063993A1
Disclosed is a serotonin 5-HT2c receptor activator containing a compound represented by the formula (I) below or a salt thereof. (In the formula, the symbols are as defined in the description.)  
WO/2009/057086A1
The present invention provides R,R'-atracurium salts, processes for producing and purifying such salts, and methods of using such salts to produce highly pure cisatracurium besylate.  
WO/2009/054501A1
Use of a carbon dioxide-supplying unit for muscle strengthening makes it possible conveniently strengthen a target muscle within a short period of time merely by allowing the target site to absorb carbon dioxide without loading any a mec...  
WO/2009/054725A2
The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combine...  
WO/2009/054725A3
The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combine...  
WO/2009/051244A1
Disclosed is a compound represented by the following formula (I). (In the formula, the symbols are as defined in the description.) This compound has an excellent RBP4 lowering effect, and is useful as an agent for prevention or treatment...  
WO/2009/044383A1
The present invention relates to a nucleic acid molecule comprising a nucleotide sequence codifying for a protein characterized in having at least four zinc finger domains and in modulating the transcription of the utrophin gene by bindi...  
WO/2009/044787A1
It is clarified that the inhibition of the expression or function of tenomodulin induces a disease relating to the rupture of a tendon such as CTC. It is expected that tenomodulin protein or a substance capable of activating the expressi...  
WO/2009/044383A8
The present invention relates to a nucleic acid molecule comprising a nucleotide sequence codifying for a protein characterized in having at least four zinc finger domains and in modulating the transcription of the utrophin gene by bindi...  
WO/2009/040814A1
The invention provides an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide and a Copolymer 1-related polypeptide, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions...  
WO/2009/042907A1
Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 express...  
WO/2009/036590A1
The present invention relates to novel compounds from Antrodia cinnamomea and their use.  
WO/2009/038110A1
Disclosed is a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which comprises, as an active ingredient, any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms ...  
WO/2009/036149A9
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  
WO/2009/036149A3
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  
WO/2009/033250A1
A nutritional supplement comprising a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ing...  
WO/2009/036149A2
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  
WO/2009/033130A1
Compositions and methods for treating mitochondrial disorders are provided. The compositions include compounds having a mitochondrial targeting moiety, for example a lipophilic cation. Certain compounds are effective for increasing the r...  
WO/2009/025149A1
The object is to identify a receptor for ADNF to elucidate a specific signaling pathway of the anti-ALS activity of ADNF, and to provide a screening system for identifying a compound capable of binding to the ADNF receptor or a compound ...  
WO/2009/025091A1
Disclosed is a novel therapeutic agent for fibromyalgia. A pharmaceutical composition comprising tizanidine as an active ingredient can be used as a therapeutic agent for fibromyalgia. The pharmaceutical composition can ameliorate a pain...  
WO/2009/021750A3
There are disclosed compounds of Formula (1). Pharmaceutical compositions containing the compounds are also provided. Methods of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy and cachexia using the compounds and com...  
WO/2009/021747A3
There are provided compounds of Formula (I) wherein three of A1, A2, A3, and A4 represent CH and one of A1, A2, A3, and A4 represents CR1; R1 represents SO2R2 or NHCOR2 wherein R2 represents C1-C6 alkyl optionally substituted by one or m...  
WO/2009/021747A2
There are provided compounds of Formula (I) wherein three of A1, A2, A3, and A4 represent CH and one of A1, A2, A3, and A4 represents CR1; R1 represents SO2R2 or NHCOR2 wherein R2 represents C1-C6 alkyl optionally substituted by one or m...  
WO/2009/022687A1
Disclosed is a compound represented by the following general formula (I). (I) (In the formula, R1 represents a hydrogen atom or the like; R2 and R3 independently represent a hydrogen atom, an optionally oxidized C1-C4 alkyl group or an o...  
WO/2009/019027A1
Myogenesis in mammals can be promoted by a prenatal administration of 25-hydroxy vitamin D3 (25-OH D3). The 25-OH D3 can be administered to the pregnant mother, and the amount of muscle tissue in the offspring is increased relative to co...  

Matches 701 - 750 out of 17,007